Biomarin Pharmaceutical Inc (MIL:1BMRN)
€ 70.52 0 (0%) Market Cap: 13.37 Bil Enterprise Value: 13.42 Bil PE Ratio: 71.45 PB Ratio: 2.86 GF Score: 62/100

Biomarin Pharmaceutical Inc at Barclays Virtual Gene Editing & Gene Therapy Summit Transcript

Nov 16, 2020 / 06:00PM GMT
Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst

Okay. Welcome, everyone. My name is Gena Wang. I'm smid-cap biotech analyst at the Barclays. It's my great pleasure to introduce our next presenting company, BioMarin. With me on the call at the meeting, we have Hank Fuchs, President of Worldwide R&D; we have Brian Mueller, EVP and Chief Financial Officer. We also have Traci McCarty, VP, Investor Relations.

Okay. So with that, maybe we will start. Hank, I know you won't have a slide presentation, but maybe you can start with a brief introduction about BioMarin, and we will dive right into the Q&A.

Henry J. Fuchs;Brian
BioMarin Pharmaceutical Inc. - President of Worldwide Research & Development

Sure. Maybe Brian and I could tag team the brief introduction because the company has quite a lot of strength, both in terms of R&D pipeline advancement -- recent history of R&D pipeline and advancement in new commercial products. So maybe, Brian, do you want to start, kind of give a quick thumbnail on...

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot